


REMARKS

A Restriction Requirement under 35 U.S.C. §121 has been entered in the present application. The Restriction Requirement identifies inventions of Groups I through XV.

In order to be fully responsive to the restriction requirement, Applicant provisionally elects Group IX (claims 49-53, 59, and 62-75), without prejudice to Applicant's right to prosecute any non-elected subject matter in one or more continuation, continuation-in-part or divisional applications.

Further, Applicant has been required to elect a single disclosed species (specifically, a compound name and corresponding structure). In order to be fully responsive to the requirement, Applicant elects cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 H-isoindol-4-yl}-amide recited in claim 59. The corresponding structure is as follows:



Applicant has been required to elect a particular type of pain to be treated with aforementioned invention. In order to fully responsive to the requirement, Applicant elects complex regional pain syndrome recited in claims 68 and 69.

Applicant has been required to elect the presence or absence of at least one second active agent. In order to be fully responsive to the requirement, Applicant elects the absence of a second active agent.

No fee is believed to be due in connection with this; however, should any fee be required, Applicant hereby authorizes that such fee be charged to Deposit Account No. 50-3013.

Date: March 6, 2008

Respectfully submitted,

By: Yeah-Sil Moon

(Reg. No.) 52,042

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939